Epuration d'olmesartan medoxomil

Purification of olmesartan medoxomil


The present invention provides a process for purifying olmesartan medoxomil.
La présente invention a trait à un procédé pour l'épuration d'olmesartan medoxomil.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    US-5616599-AApril 01, 1997Sankyo Company, LimitedAngiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use

NO-Patent Citations (1)

    See also references of EP 1784398A1

Cited By (34)

    Publication numberPublication dateAssigneeTitle
    CN-102414200-AApril 11, 2012第一三共株式会社奥美沙坦酯的制备方法
    EP-1891952-A1February 27, 2008LEK Pharmaceuticals D.D.Pharmazeutische Zusammensetzung
    EP-1916246-A2April 30, 2008Cadila Pharmaceuticals LimitedAn improved process for the preparation of olmesartan medoxomil
    EP-1916246-A3June 18, 2008Cadila Pharmaceuticals LimitedVerbesserter Herstellungsprozess für Olmesartanmedoxomil
    EP-2033643-A1March 11, 2009Daiichi Sankyo Company, LimitedCompressed preparation
    EP-2033643-A4January 02, 2013Daiichi Sankyo Co LtdKomprimierte zubereitung
    EP-2253318-A1November 24, 2010Daiichi Sankyo Company, LimitedImprovement of dissolvability of preparation containing olmesartan medoxomil
    EP-2253318-A4February 23, 2011Daiichi Sankyo Co LtdImprovement of dissolvability of preparation containing olmesartan medoxomil
    EP-2426126-A1March 07, 2012Daiichi Sankyo Company, LimitedVerfahren zur herstellung von olmesartan-medoxomil
    EP-2426126-A4October 17, 2012Daiichi Sankyo Co LtdProcédé de production de l'olmésartan médoxomil
    GB-2454620-AMay 13, 2009Daiichi Sankyo Co LtdSolid dosage form of olmesartan medoxomil and amlodipine
    GB-2454620-BAugust 17, 2011Daiichi Sankyo Co LtdSolid dosage form of olmesartan medoxomil and amlodipine
    GB-2471970-AJanuary 19, 2011Daiichi Sankyo Co LtdComposition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide
    KR-101676512-B1November 15, 2016다이이찌 산쿄 가부시키가이샤Method for producing olmesartan medoxomil
    KR-20120006512-AJanuary 18, 2012다이이찌 산쿄 가부시키가이샤Method for producing olmesartan medoxomil
    US-8652519-B2February 18, 2014Daiichi Sankyo Company, LimitedDissolution properties of drug products containing olmesartan medoxomil
    US-8735598-B2May 27, 2014Daiichi Sankyo Company, LimitedMethod for producing 1-biphenylmethylimidazole compound
    US-8859600-B2October 14, 2014Daiichi Sankyo Company, LimitedAcetone solvate crystals of trityl olmesartan medoxomil
    US-8933241-B2January 13, 2015Daiichi Sankyo Company, LimitedMethod for producing olmesartan medoxomil
    US-9034874-B2May 19, 2015Novartis AgCarbamate/urea derivatives
    US-9273026-B2March 01, 2016Novartis AgCarbamate/urea derivatives
    US-9624192-B2April 18, 2017Novartis AgCarbamate/urea derivatives
    US-9707178-B2July 18, 2017Lek Pharmaceuticals, D.D.Pharmaceutical composition
    WO-2007128478-A2November 15, 2007Lek Pharmaceuticals D.D.Composition pharmaceutique
    WO-2007128478-A3February 07, 2008Lek Pharmaceuticals, Matej Avanzo, Peterka Tanja Rozman, Igor LegenComposition pharmaceutique
    WO-2008032107-A1March 20, 2008Daiichi Sankyo Company Limited, Fairbairn, Angus, ChrisholmForme posologique solide d'olmesartan medoxomil et d'amlodipine
    WO-2008149155-A1December 11, 2008Generics [Uk] LimitedForme cristalline b d'olmesartan médoxomil
    WO-2010076596-A1July 08, 2010Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim SirketiFormulations pharmaceutiques d'olmésartan
    WO-2010126013-A1November 04, 2010第一三共株式会社Method for producing olmesartan medoxomil
    WO-2010126014-A1November 04, 2010第一三共株式会社Novel solvate crystals
    WO-2010134052-A1November 25, 2010Ranbaxy Laboratories LimitedProcess for the preparation of olmesartan medoxomil
    WO-2011021224-A2February 24, 2011Msn Laboratories LimitedProcess for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
    WO-2011021224-A3April 28, 2011Msn Laboratories LimitedImproved process for preparing (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-(tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
    WO-2012055380-A1May 03, 2012Zentiva, K. S.A method of obtaining olmesartan medoxomil